Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis

被引:26
|
作者
Skeldal, Sune
Larsen, Jakob V.
Pedersen, Katrine E.
Petersen, Helle H.
Egelund, Rikke
Christensen, Anni
Jensen, Jan K.
Gliemann, Jorgen
Andreasen, Peter A.
机构
[1] Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark
[2] Univ Aarhus, Interdisciplinary Nanosci Ctr iNANO, Aarhus, Denmark
[3] Univ Aarhus, Dept Biochem Med, Aarhus, Denmark
关键词
low-density lipoprotein receptor-related protein; plasminogen activator inhibitor 1; sorting protein-related receptor; urokinase plasminogen activator; very-low-density lipoprotein receptor;
D O I
10.1111/j.1742-4658.2006.05511.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Some endocytosis receptors related to the low-density lipoprotein receptor, including low-density lipoprotein receptor-related protein-1A, very-low-density lipoprotein receptor, and sorting protein-related receptor, bind protease-inhibitor complexes, including urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1), and the uPA-PAI-1 complex. The unique capacity of these receptors for high-affinity binding of many structurally unrelated ligands renders mapping of receptor-binding surfaces of serpin and serine protease ligands a special challenge. We have mapped the receptor-binding area of the uPA-PAI-1 complex by site-directed mutagenesis. Substitution of a cluster of basic residues near the 37-loop and 60-loop of uPA reduced the receptor-binding affinity of the uPA-PAI-1 complex approximately twofold. Deletion of the N-terminal growth factor domain of uPA reduced the affinity 2-4-fold, depending on the receptor, and deletion of both the growth factor domain and the kringle reduced the affinity sevenfold. The binding affinity of the uPA-PAI-1 complex to the receptors was greatly reduced by substitution of basic and hydrophobic residues in alpha-helix D and alpha-helix E of PAI-1. The localization of the implicated residues in the 3D structures of uPA and PAI-1 shows that they form a continuous receptor-binding area spanning the serpin as well as the A-chain and the serine protease domain of uPA. Our results suggest that the 10-100-fold higher affinity of the uPA-PAI-1 complex compared with the free components depends on the bonus effect of bringing the binding areas on uPA and PAI-1 together on the same binding entity.
引用
收藏
页码:5143 / 5159
页数:17
相关论文
共 50 条
  • [1] Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein
    Andersen, OM
    Petersen, HH
    Jacobsen, C
    Moestrup, SK
    Etzerodt, M
    Andreasen, PA
    Thogersen, HC
    BIOCHEMICAL JOURNAL, 2001, 357 (01) : 289 - 296
  • [2] Binding of urokinase-type plasminogen activator plasminogen activator inhibitor-1 complex to the endocytosis receptors α2-macroglobulin receptor low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor
    Rodenburg, KW
    Kjoller, L
    Petersen, HH
    Andreasen, PA
    BIOCHEMICAL JOURNAL, 1998, 329 : 55 - 63
  • [3] Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and-2 in hepatocellular carcinoma
    Zhou, L
    Hayashi, Y
    Itoh, T
    Wang, WP
    Rui, JA
    Itoh, H
    PATHOLOGY INTERNATIONAL, 2000, 50 (05) : 392 - 397
  • [4] VERY-LOW-DENSITY LIPOPROTEIN RECEPTOR BINDS AND MEDIATES ENDOCYTOSIS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR-TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR COMPLEX
    HEEGAARD, CW
    SIMONSEN, ACW
    OKA, K
    KJOLLER, L
    CHRISTENSEN, A
    MADSEN, B
    ELLGAARD, L
    CHAN, L
    ANDREASEN, PA
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (35) : 20855 - 20861
  • [5] There is no covalent interaction between plasminogen activator inhibitor-1 with urokinase-type plasminogen activator
    Wang, Q
    Shaltiel, S
    MOLECULAR BIOLOGY OF THE CELL, 2002, 13 : 513A - 513A
  • [6] Structural Basis for Recognition of Urokinase-type Plasminogen Activator by Plasminogen Activator Inhibitor-1
    Lin, Zhonghui
    Jiang, Longguang
    Yuan, Cai
    Jensen, Jan K.
    Zhang, Xu
    Luo, Zhipu
    Furie, Barbara C.
    Furie, Bruce
    Andreasen, Peter A.
    Huang, Mingdong
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (09) : 7027 - 7032
  • [7] Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis
    Gårdsvoll, H
    Dano, K
    Ploug, M
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (53) : 37995 - 38003
  • [8] UROKINASE-TYPE PLASMINOGEN-ACTIVATOR, UROKINASE-TYPE PLASMINOGEN-ACTIVATOR RECEPTOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 I IN BREAST-CANCER CELLS
    WAJIMA, T
    DEGEN, D
    ORIZ, V
    VONHOFFOLIN, DD
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1284 - 1284
  • [9] Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19
    Yatsenko, Tetiana
    Rios, Ricardo
    Nogueira, Tatiane
    Takahashi, Satoshi
    Tabe, Yoko
    Naito, Toshio
    Takahashi, Kazuhisa
    Hattori, Koichi
    Heissig, Beate
    FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [10] Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients
    Chung, HC
    Rha, SY
    Park, JO
    Yoo, NC
    Kim, JH
    Roh, JK
    Min, JS
    Lee, KS
    Kim, BS
    Kim, JJ
    BREAST CANCER RESEARCH AND TREATMENT, 1998, 49 (01) : 41 - 50